| Drug Type Monoclonal antibody | 
| Synonyms TATX 27, TATX27 | 
| Target | 
| Action inhibitors | 
| Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 12 Oct 2022 | |
| Hematologic Neoplasms | Discovery | United States  | 01 Mar 2025 | |
| Hematologic Neoplasms | Discovery | United States  | 01 Mar 2025 | |
| Hematologic Neoplasms | Discovery | Belgium  | 01 Mar 2025 | 






